- Gene Therapy Improves Vision in People With Inherited Blindness
- Parental Deaths to Guns, Drugs Harmed Nearly 100,000 U.S. Kids in 2020
- Money Worries Top Seniors’ List of Health-Related Concerns: Poll
- Scientists Developing Vaccine Against Present and Future COVID Viruses
- ERs Often Missing Epilepsy in Kids With ‘Non-Motor’ Seizures
- Parents of Infants With Cystic Fibrosis Often Feel Confused, Unsupported: Survey
- Avoid Some ‘Project Watson’ Dog Eye Wipes Due to Infection Danger
- New Test Might Alert Pregnant Women to Preeclampsia Danger
- Combo Therapy May Be Advance Against Liver Cancer
- How ‘Unruly’ Sports Parents Harm Their Kids’ Mental Health
Vistogard Approved for Chemotherapy Overdose
Vistogard (uridine triacetate) has been approved by the U.S. Food and Drug Administration to treat an overdose of chemotherapy drugs commonly used to treat cancers of the breast and gastrointestinal tract.
The drugs are fluorouracil and capecitabine. An overdose of either drug, while rare, can be life-threatening, the FDA said Friday in a news release.
Treatment with Vistogard should begin as soon as possible after the overdose, even if any symptoms of overdose aren’t present, the agency warned. The user’s doctor should then determine when a return to chemotherapy is appropriate.
Vistogard is designed to minimize cell damage caused by chemotherapy. The drug was evaluated in clinical studies involving 135 children and adults who either had taken an overdose of chemotherapy or had developed a life-threatening toxic reaction within 96 hours of being given chemotherapy. Of clinical trial participants given Vistogard, 89 percent to 97 percent were still alive after 30 days, the agency said.
Vistogard is not recommended for non-emergency adverse reactions associated with chemotherapy, as the new drug could weaken the effects of chemotherapy, the FDA said. Vistogard’s most common side effects included diarrhea, vomiting and nausea.
Vistogard is marketed by Gaithersburg, Md.-based Wellstat Therapeutics.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.